Winning the Cold War

Jolda, Deb
July 2000
Applied Clinical Trials;Jul2000, Vol. 9 Issue 7, p48
Academic Journal
Interviews a participant involved in the clinical trials of a drug for the treatment of the common cold. Payment received for participating in the trial; Knowledge on the clinical trial processes; Absence of side effects of the drug; Professionalism displayed by the staff conducting the trials.


Related Articles

  • Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs. Denis, Alain; Mergaert, Lut; Fostier, Christel; Cleemput, Irina; Hulstaert, Frank; Simoens, Steven // PharmacoEconomics;2011, Vol. 29 Issue 10, p883 

    Background: Orphan medicinal products are designed to diagnose or treat rare diseases that are serious, life threatening or chronically debilitating and that affect 50 or fewer people in every 100 000 in the EU. In Belgium, the Drug Reimbursement Committee (DRC) evaluates reimbursement requests...

  • How to Find a Trial. Smith, Ian K. // Time International (South Pacific Edition);11/22/99, Issue 47, p76 

    Offers information on patient enrollment in clinical drug trials. Researchers' need for patients as well as patients' need for treatment; Reasons adults do not participate in clinical drug trials; Where to locate trials. INSETS: Ace-ing It;Inside Information;Minitel Mini-Stroke;Couch Potatoes...

  • Malaria: Joint attack on malaria. Ellis, Clare // Nature Reviews Microbiology;Sep2004, Vol. 2 Issue 9, p689 

    The article reports on the success of the study conducted by a group of international scientists that to develop a new antimalarial drug. The team, that is consists of researchers from universities and medical-related institutions worldwide, aims to identify a new synthetic peroxide antimalarial...

  • Retention rate good for difficult population.  // Clinical Trials Administrator;Oct2008, Vol. 6 Issue 10, p114 

    The article outlines some key strategies to retaining clinical trial (CT) enrollment, particularly when participants are from vulnerable population. Clinical nurse specialist Pamela Normandin emphasizes the need for making numerous follow-up calls. She cites some of the small amenities that can...

  • Conducting Trials in Croatia. Aralica, Josip // Applied Clinical Trials;Nov2009, Vol. 18 Issue 11, p46 

    The article reports on the clinical research projects in Croatia while not being part of the European Union (EU). It mentions that European countries, even if not part of the EU, is not a hindrance to producing high-quality clinical research and meeting the target for the number of subjects....

  • Great Expectations: CROs Face Change in Italy. Corrado, Mario // Applied Clinical Trials;Nov2009, Vol. 18 Issue 11, p50 

    The article reports on the turbulent period of the clinical trials in Italy. It states that the country has a heterogeneous topology of the Contract Research Organizations (CRO) while the number of new trials per year has increased consistently from 500 in 2000 to 800 in 2007. On the other hand,...

  • Facebook used to find trial volunteers. O'Reilly, Gemma // PRWeek (London);8/1/2008, p6 

    The article talks about the efforts of pharmaceutical companies to recruit clinical trial subjects online through Facebook and blogs. Drug companies were noted to be asking healthcare public relations (PR) agencies to be more innovative to promote the benefits of being involved in drug trials...

  • The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? Taddei, Angela; Roche, Danièle; Bickmore, Wendy A.; Almouzni, Geneviève // EMBO Reports;Jun2005, Vol. 6 Issue 6, p520 

    Histone acetylation regulates many chromosome functions, such as gene expression and chromosome segregation. Histone deacetylase inhibitors (HDACIs) induce growth arrest, differentiation and apoptosis of cancer cells ex vivo, as well as in vivo in tumour-bearing animal models, and are now...

  • My Most Difficult Choice. Saporito, Bill; Park, Mice // Time International (South Pacific Edition);5/23/2005, Issue 20, p48 

    The article presents the views of the authors on the clinical trials concerning heart risks of COX-2 inhibitors such as Celebrex and Vioxx, commonly used as anti-inflammatory drugs, also effective in fighting or preventing cancer. Hundreds of patients are participating in clinical trials to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics